JP2005506061A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506061A5
JP2005506061A5 JP2003514002A JP2003514002A JP2005506061A5 JP 2005506061 A5 JP2005506061 A5 JP 2005506061A5 JP 2003514002 A JP2003514002 A JP 2003514002A JP 2003514002 A JP2003514002 A JP 2003514002A JP 2005506061 A5 JP2005506061 A5 JP 2005506061A5
Authority
JP
Japan
Prior art keywords
peptide
pharmaceutical composition
composition according
disease
gland
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003514002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506061A (ja
JP4587667B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2002/001106 external-priority patent/WO2003008444A2/en
Publication of JP2005506061A publication Critical patent/JP2005506061A/ja
Publication of JP2005506061A5 publication Critical patent/JP2005506061A5/ja
Application granted granted Critical
Publication of JP4587667B2 publication Critical patent/JP4587667B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003514002A 2001-07-19 2002-07-19 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド Expired - Lifetime JP4587667B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30616101P 2001-07-19 2001-07-19
US30615001P 2001-07-19 2001-07-19
US33147701P 2001-11-16 2001-11-16
PCT/CA2002/001106 WO2003008444A2 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Publications (3)

Publication Number Publication Date
JP2005506061A JP2005506061A (ja) 2005-03-03
JP2005506061A5 true JP2005506061A5 (enExample) 2006-01-05
JP4587667B2 JP4587667B2 (ja) 2010-11-24

Family

ID=27405149

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003514002A Expired - Lifetime JP4587667B2 (ja) 2001-07-19 2002-07-19 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
JP2003514001A Pending JP2005507647A (ja) 2001-07-19 2002-07-19 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2011035954A Pending JP2011152133A (ja) 2001-07-19 2011-02-22 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2013078281A Expired - Lifetime JP5622885B2 (ja) 2001-07-19 2013-04-04 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2003514001A Pending JP2005507647A (ja) 2001-07-19 2002-07-19 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2011035954A Pending JP2011152133A (ja) 2001-07-19 2011-02-22 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2013078281A Expired - Lifetime JP5622885B2 (ja) 2001-07-19 2013-04-04 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Country Status (22)

Country Link
US (2) US7241738B2 (enExample)
EP (2) EP1417227B1 (enExample)
JP (4) JP4587667B2 (enExample)
KR (2) KR100966232B1 (enExample)
CN (1) CN100475843C (enExample)
AT (1) ATE353914T1 (enExample)
AU (2) AU2002319049B2 (enExample)
BR (2) BRPI0211200B8 (enExample)
CA (2) CA2453967C (enExample)
CY (1) CY1108009T1 (enExample)
DE (2) DE60217507T2 (enExample)
DK (1) DK1417228T3 (enExample)
EA (1) EA006603B1 (enExample)
ES (2) ES2281529T3 (enExample)
IL (2) IL159903A0 (enExample)
MX (1) MXPA04000561A (enExample)
NO (1) NO333999B1 (enExample)
NZ (2) NZ531114A (enExample)
PL (1) PL207588B1 (enExample)
PT (1) PT1417228E (enExample)
WO (2) WO2003008443A2 (enExample)
ZA (1) ZA200401320B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
BR0207638A (pt) * 2001-03-08 2004-07-27 Nymox Pharmaceuticals Corp Métodos de uso de proteìna de filamento neural para tratar tumores e outras condições que requerem a remoção ou destruição de células
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
JP4587667B2 (ja) * 2001-07-19 2010-11-24 ナイモックス コーポレーション 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
ATE445714T1 (de) * 2001-12-04 2009-10-15 Millennium Pharm Inc 15603, ein mitglied der humanen ionenkanal- familie
WO2005014635A2 (en) * 2003-07-15 2005-02-17 Genova Ltd. Secreted polypeptide species reduced in cardiovascular disorders
BRPI0412664A (pt) * 2003-07-15 2006-09-26 Ca Nat Research Council método para tratar uma condição caracterizada por hiperproliferação de células da pele em um indivìduo em risco ou portador dessa condição e utilização de uma quantidade terapeuticamente efetiva de um análogo cìclico de hormÈnio de paratireóide humano (hpth)
WO2005075647A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
US20060173490A1 (en) 2005-02-01 2006-08-03 Boston Scientific Scimed, Inc. Filter system and method
PL1994152T3 (pl) 2006-02-28 2013-05-31 Nymox Corp Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek
MX2008011570A (es) * 2006-03-10 2008-09-23 Nymox Corp Metodo para prevenir o reducir el riesgo o incidencia de cancer usando peptidos basados en proteina de hebra neural.
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
CA2990264C (en) * 2007-10-25 2022-08-09 Toray Industries, Inc. Immune response inducer
JP5572938B2 (ja) * 2007-10-25 2014-08-20 東レ株式会社 免疫誘導剤
US9539327B2 (en) * 2007-11-26 2017-01-10 The Research Foundation For The State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
EP2293809B1 (en) * 2008-04-24 2019-05-15 Therimunex Pharmaceuticals, Inc. Peptidyl diacylglycerides
US8637642B2 (en) 2010-09-29 2014-01-28 Seattle Genetics, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
CA2928526A1 (en) 2013-11-01 2015-05-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
US20160215031A1 (en) * 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) * 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) * 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) * 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
WO2019195851A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
AU2019392090A1 (en) 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927459T2 (de) * 1988-12-21 1997-04-24 Gen Hospital Corp Nachweis einer neurologischen Krankheit oder einer Funktionsstörung
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
KR20000075748A (ko) 1997-02-26 2000-12-26 마빈 씨. 구트리 알츠하이머 병의 치료 또는 예방에 유효한 약물을 선별하기 위한 유전자 변형동물 및 세포계
JP2002519311A (ja) * 1998-06-26 2002-07-02 ジョージタウン・ユニバーシティ・メディカル・センター 細胞死を誘発するための組成物と方法
US7125957B1 (en) * 1998-09-30 2006-10-24 Riken VPR mutant protein and its encoding gene having apoptosis-inducing action
WO2000034477A2 (en) 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
ES2202039T3 (es) * 1999-01-11 2004-04-01 Leadd B.V. Uso de agentes inductores de apoptosis en la preparacion de mrdicamentto para el tratamiento de enfermedades autoinmunitarias.
WO2000058339A2 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 50 human secreted proteins
JP2002542766A (ja) 1999-03-12 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
AU3628600A (en) 1999-03-19 2000-10-09 Human Genome Sciences, Inc. 46 human secreted proteins
CA2368927A1 (en) 1999-03-26 2000-10-05 Craig A. Rosen 45 human secreted proteins
JP2002541833A (ja) 1999-03-26 2002-12-10 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４９個のヒト分泌タンパク質
CN1300779A (zh) 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
CN1300783A (zh) 1999-12-23 2001-06-27 上海生元基因开发有限公司 新的人神经元线蛋白及其编码序列
EP1307488A2 (en) * 2000-06-26 2003-05-07 Millennium Pharmaceuticals, Inc. A human calcium channel protein and uses thereof
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
WO2002097030A2 (en) 2001-05-25 2002-12-05 Nymox Corporation Peptides derived from neural thread proteins and their medical use
JP4587667B2 (ja) * 2001-07-19 2010-11-24 ナイモックス コーポレーション 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド

Similar Documents

Publication Publication Date Title
JP2005506061A5 (enExample)
JP2005521383A5 (enExample)
JP2005507647A5 (enExample)
JP2004534533A5 (enExample)
ES2255248T3 (es) Derivados de antigenos asociados a tumor de la familia mage, y secuencias de acidos nucleicos que los codifican, usados para la preparacion de proteinas de fusion y de composiciones para vacunas.
JP2004529908A5 (enExample)
JP3487597B2 (ja) 筋細胞内での発現のためのウイルス性組換え型ベクター
JP2003531632A (ja) グルカゴンアンタゴニスト
US20080057064A1 (en) Erbb3 Based Methods and Compositions for Treating Neoplasms
EP2281040B1 (en) Lyophilized dna formulations for enhanced expression of plasmid dna
ES2260219T3 (es) Derivados de peptidos apo-ai/aii.
JP2005530484A5 (enExample)
US20210403948A1 (en) Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof
JP2004528266A (ja) 薬物送達用組成物
JPWO2019140283A5 (ja) アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物
PT98695A (pt) Gene codificador do factor neurotrofico de ligacao a heparina
CA2378925A1 (en) Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
JP2002505847A (ja) Ｒｈｉｐｉｃｅｐｈａｌｕｓａｐｐｅｎｄｉｃｕｌａｔｕｓ由来の組織セメントタンパク質
RU2013113639A (ru) Иммунотерапевтический способ лечения рака простаты
CN100435848C (zh) 提高饲料效率和家畜生长速度的基因处理
JPWO2020084162A5 (enExample)
ES2302731T3 (es) Compuestos y procedimientos para reducir los niveles de colesterol sin inducir hipertrigliceridemia.
CN118064445A (zh) 改进的bFGF编码序列及其修饰细胞的应用
CN100535005C (zh) 长链人胰岛素样生长因子(lr3igf-1)及其制备和应用方法
US11459364B2 (en) Calbindin and BH3 domain chimeric proteins and methods for use